. Author manuscript; available in PMC: 2013 Jun 9.

Published in final edited form as: Biol Blood Marrow Transplant. 2010 Sep 24;17(7):979–986. doi: 10.1016/j.bbmt.2010.09.014

Table 3.

Univariable analysis of impact of URI antiviral therapy in hematopoietic cell transplant recipients with influenza infection (N = 142)

	URI antiviral therapy
Clinical outcome	No (N = 84)	Yes (N = 58)	OR or HR^* (95% CI)	P
	N (%)	N (%)	OR or HR^* (95% CI)
Lower respiratory tract diseases	29 (35)	3 (4)	0.1 (0.0-0.4)	< 0.01
Hypoxemia	26 (31)	6 (10)	0.3 (0.1-0.8)	0.01
Mechanical ventilation	10 (12)	3 (4)	0.5 (0.1-1.8)	0.25
Influenza-associated deaths^†	10 (12)	2 (2)	0.3 (0.0-1.2)	0.09
Deaths^†	14 (17)	3 (4)	0.3 (0.1-1.0)	0.05
Prolonged shedding^‡	16 (34)	9 (23)	0.6 (0.2-1.5)	0.27

CI indicates confidence interval; HR, hazard ratio, OR, odds ratio; URI, upper respiratory tract infection.

Odds ratio are shown lower respiratory tract disease, hypoxemia, mechanical ventilation and prolonged shedding and hazard ratio are shown for time to death and influenza associated death.

^†

During the first 42 days following influenza diagnosis.

^‡

Defined as viral excretion > 14 days. Only 87 patients with available data for this analysis.